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ABSTRACT
Human placenta undergoes both angiogenesis and vasculogenesis during fetal development. An imbalance in proangiogenic
[placental growth factor (PlGF) and vascular endothelial growth factor] and antiangiogenic factors [soluble fms like tyrosine
kinase-1 (sFlt-1), soluble endoglin (sEng)] has been reported to have a role in pathophysiology of preeclampsia. Hence the
present study was designed to analyze heme oxygenase-1 and endoglin levels in maternal and cord blood of normotensive
women. The study comprised of twenty five normotensive pregnant women immediately after delivery Study samples were
drawn (maternal venous blood and umbilical cord blood) and heme oxygenase-1 (HO-1) and endoglin levels were analyzed by
competitive enzyme linked immunosorbent assay. Heme oxygenase-1 levels were elevated in maternal blood as compared to
cord blood of normotensive pregnant women. Also, serum blood endoglin levels were higher in maternal blood compared to
cord blood of normotensive pregnant women. These findings indicate that there is angiogenic balance during normotensive
pregnancy and dysbalance might occur during pathological pregnancy. These markers of angiogenic balance may serve as
diagnostic marker and may help in explaining future risk of cardiovascular disease in these women.
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INTRODUCTION
During pregnancy, there is coordinated formation of
new blood vessels (termed as angiogenesis). Vascular
growth factors, vascular endothelial growth factor and
placental growth factor, promote remodelling of the
maternofetal interface. Placental and maternal
vasculatures are major sources of reactive oxygen and
nitrogen species that alter vascular function in
preeclampsia. Placental hypoxia and maternal vascular
dysfunction occur by linking of placental
syncytiotrophoblast basement membranes shedding with
placental angiogenic factors [soluble flt1 and endoglin].
Endoglin binds vascular endothelial growth factor (VEGF)
and placental growth factor (PIGF)] in the maternal
circulation [1,2].
Angiogenesis is critical in establishing a functional
placenta during pregnancy. During preeclampsia,
insufficient maternal spiral artery remodelling occurs due
to defective endovascular invasion by cytotrophoblasts
and impaired vasculogenesis [1,2]. Normally, there is a
balance between proangiogenic and antiangiogenic
factors in the developing placenta. Deregulation of
angiogenesis in placenta and maternal circulation results
in placental insufficiency and its further consequences
such as fetal growth restriction and maternal
preeclampsia. In the event of any imbalance in
proangiogenic [placental growth factor (PlGF) and
vascular endothelial growth factor] and antiangiogenic
factors [soluble fms like tyrosine kinase-1 (sFlt-1), soluble
endoglin (sEng)], angiogenesis will be altered and
preeclampsia may ensue [1-3].
The main determinants of vasodilatory and angiogenic
reserve are angiogenic growth factors (GFs) resulting in a
favorable anti- to pro-angiogenic balance in pregnant
women. HO-1 maintains uterine quiescence and
overexpression of HO-1 has been reported to decrease
the production of sFlt-1 and sEng. The concept that HO-1
acts as a negative regulator of sFlt-1 and sEng release also
indicates that this cascade offers vascular protection
against pregnancy induced oxidative stress and
exacerbated inflammation. It has already been reported
that protein levels of HO-1 in preeclamptic placenta are
decreased. The angiogenic balance in preeclampsia might
be influenced by HO/CO-system [3,4]. The present study
explored a range of HO-1 and endoglin as a potential
marker of angiogenic balance and their association with
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Limited information is available regarding
pathophysiological events of fetoplacental side during
gestation and placenta terminates self-role as the
fetomaternal mediator soon after the delivery. Altered
antiangiogenic signaling and unfavorable
proinflammatory cytokines production by placenta have
been implicated in pathophysiology of preeclampsia [3,4].
This article aimed to explore association of maternal
characteristics and fetal outcome with angiogenic factors
of normotensive pregnant women.
MATERIALS AND METHODS
The study was carried out in the Departments of
Biochemistry and Obstetrics and Gynaecology, Pt. B.D.
Sharma, PGIMS, Rohtak. Serum heme oxygenase-1(HO-1),
endoglin and lipid profile were analyzed in maternal and
cord blood in normotensive pregnant women. An
informed consent was taken from all the patients and the
research protocol was approved by the Institutional
Review Board. Women with history of smoking, any
metabolic disorder before or during pregnancy or
presence of high risk factors like anemia, heart disease,
diabetes, renal disease, history of any vitamin
supplement were excluded from the study. All clinical
data were collected after the initial preeclampsia
evaluation including age, height, weight, smoking status,
gestational age, clinical findings, BP, and the results of
laboratory tests were included. Also, pregnancy
outcomes including complications and delivery
characteristics were recorded.
Twenty five pregnant women with singleton
pregnancies who remained normotensive (defined as
BP<140/90) throughout the pregnancy were selected and
study samples (maternal venous blood and umbilical cord
blood) were drawn immediately after delivery. Heme
oxygenase-1 was analyzed by competitive enzyme linked
immunosorbent assay (QAYEE-BIO) [5]. RayBio® Human
Endoglin (CD105) ELISA (Enzyme-Linked Immunosorbent
Assay) kit was used for the quantitative measurement of
human Endoglin in blood.6 The intra-assay and inter-
assay coefficients of variation were <10% and <12%.
Lipid profile was analyzed enzymatically. All the analyses
were performed by using the statistical package (SPSS
20). The values were compared with non-pregnant
control values.
RESULTS
The mean age of normotensive women was 24.16 ±
1.86 years and mean gestational age at time of delivery
was 37.52 ± 0.59 weeks. Gestational age of mothers
ranged from 34-41 weeks at time of delivery. Majority of
the babies had birth weight between 2.1-2.5 kg and mean
birth weight was 2.34+0.19 kg. Majority had vaginal
delivery in normotensive mothers. Mean birth weight in
normotensive women was 2.34 ± 0.19 kg. Majority of
the babies were born with good Apgar score. Majority of
mother had vaginal delivery 84% and assisted deliveries
(vacuum/ forceps) in 2%.
The maternal heme oxygenase-1 (HO-1) were higher as
compared with cord blood (277.20 ± 32.24 ng/dl and
276.60 ± 31.62ng/dl respectively). The maternal endoglin
were higher as compared with cord blood (6.64 ± 0.34
ng/dl and 6.60 ± 0.28ng/dl respectively).
Maternal HO-1 were higher in mothers with female
babies as compared to male babies (285.30 ± 28.40 vs.
268.41 ± 35.00 ng/ml, p>0.05). Cord blood HO1 were
higher in female babies as compared to male babies
(279.23 ± 30.95 ng/ml vs. 273.75 ± 33.45 ng/ml,
p>0.05). Cord blood heme oxygenase 1 was 99.78% of
maternal levels and cord blood endoglin levels were
99.39% of maternal levels.
There was a negative correlation between maternal
heme oxygenase 1 and maternal endoglin in
normotensive pregnant women (r=-0.039, p>0.05).
Positive correlation was observed between cord blood
HO1 and cord blood endoglin in normotensive pregnant
women (r=0.159, p>0.05).
Negative correlation was observed between cord blood
HO1 with gestational age (r=-0.209, p>0.05). Negative
correlation was observed between cord blood endoglin
and gestational age (r=-0.167, p>0.05).
Positive correlation was observed between maternal
HO1 levels with birth weight (r=0.098, p>0.05). Positive
correlation was observed between cord blood HO1 and
birth weight (r=0.186, p>0.05). Significant positive
correlation was observed between cord blood endoglin
and birth weight (r=0.404, p<0.05).
In the present study, maternal HO-1 showed positive
correlation with MBP (mean blood pressure) in
normotensive women, however, it was not statistically
significant (r=0.116, p>0.05). In the present study,
maternal HO1 showed a positive correlation with systolic
blood pressure in normotensive women (r=0.169,
p>0.05). Maternal HO1 showed a positive correlation
with diastolic blood pressure in normotensive women,
however, it was not statistically significant (r=0.396,
p>0.05).
Maternal HO 1 levels in the present study showed a
positive correlation with Hb in normotensive women but
it was not statistically significant (r=0.166, p>0.05). In
the present study, serum bilirubin levels were 0.70 +
0.12 mg/dl in normotensive pregnant women. Serum
bilirubin levels negatively correlated with HO 1 levels in
normotensive pregnant women (r= -0.292, p>0.05).
In the present study, Maternal LDL levels were
negatively correlated in normotensive women (r=-0.111,
p>0.05). Cord blood LDL levels were positively correlated
in normotensive women (r=0.142, p>0.05).
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DISCUSSION
Coordinated formation of new blood vessels during
pregnancy occurs under influence of vascular growth
factors, vascular endothelial growth factor (VEGF) and
placental growth factor (PIGF) that promote remodelling
of the maternofetal interface. Soluble flt1 and endoglin
are placental angiogenic factors and endoglin binds
vascular endothelial growth factor and placental growth
factor in the maternal circulation [4-6]. For normal
placental function, fine balance between angiogenic and
anti angiogenic signaling is very important and any
dysregulation in expression of key angiogenic factors may
contribute to a number of obstetric complications
including preeclampsia.
The maternal heme oxygenase-1 was higher as
compared with cord blood and maternal endoglin were
higher as compared with cord blood [Table 1]. Padmini et
al. reported decreased expression of HO-2 in cord blood
RBC of preeclamptic subjects compared to normotensive
subjects [7]. Cord blood heme oxygenase 1 was 99.78% of
maternal levels and cord blood endoglin levels were
99.39% of maternal levels. To the best of our knowledge
no study is available regarding cord blood HO-1 in normal
pregnancy.
 HO-1 (ng/dl) Endoglin (ng/dl)


















*p<0.05 as compared to group-I
**p<0.001 as compared to group-I
Table 1: Maternal and cord blood heme oxygenase-1 and endoglin
levels in both groups [(ng/ml, mean + SD].
Negative correlations were observed between cord
blood HO1 and endoglin with gestational age (r=-0.209;
r=-0.167, p>0.05). Significant positive correlation was
observed between cord blood endoglin and birth weight
(r=0.404, p<0.05). Negative correlation was observed
between gestational age and both cord blood HO-1 and
endoglin levels. The effect of gestational age at delivery
on the differences in level is not known and further
studies are required in this aspect to explore whether
primary pathology is uteroplacental response to fetal
placental vasculature or uterine circulation constraints on
placenta and fetus.
Low birth weight have been reported to predict
predisposition to atherosclerotic cardiovascular diseases
in later life [8,9]. Also, reduced fetal growth carries a risk
of hypertension and ischemic heart disease in later years
[10-12]. A significant positive correlation was observed
between cord blood endoglin and birth weight (r=0.404,
p<0.05). Endoglin and soluble endoglin expression have
been reported to be significantly increased in placentas
of IUGR singletons compared to controls [13]. Laskowska
et al. reported increased endoglin levels in women with
normotensive pregnancy complicated by IUGR and in
preeclamptics with and without IUGR [14]. However, levels
of sEng at term pregnancy are not known. On reviewing
the literature, no reports are available where HO-1 and
birth weight have been compared.
A positive correlation was found between maternal
HO-1 and MAP normotensives suggesting that HO-1 plays
a role in maternal vascular tone regulation and HO-1
deficiency can induce elevations in maternal diastolic
blood pressure. Zhao et al. reported association of
diastolic blood pressure with HO-1 deficiency [12],
suggesting that HO-1 plays a role in regulation of
maternal vascular tone. Thus agents that increase HO
expression and reduce release of antiangiogenic factors
may be beneficial as therapeutic agents in preeclampsia.
George et al. have demonstrated that pharmacological
inhibition of HO-1 in late pregnancy caused a significant
increase in MBP and it was associated with decrease
VEGF production by the placenta and elevated placental
NADPH oxidase, major sources of superoxide [15].
In the present study, both maternal heme oxygenase 1
and endoglin levels were higher as compared to cord
blood counterparts in normotensive pregnant women.
Antiangiogenic profile defined in terms of HO-1/Eng
ratio was 41.76 in normotensive pregnant women. In
normotensive HO/Eng+ IGF were lower (0.76) in
normotensive pregnant and 16 (64%) subject had
HO-1/Eng also less than 41.76. For a successful
pregnancy, there needs to be a balance of pro- and
antiangiogenic proteins. If the normal physiologic
increase in antiangiogenic factors towards the end of
pregnancy occurs too soon and/or if there is an excess
production of the antiangiogenic proteins, preeclampsia
may result.
Maternal HO1 were higher in mothers with female
babies as compared to male babies. Cord blood HO1 was
higher in female babies as compared to male babies.
Gender-based differences in the incidence of
hypertensive and coronary artery disease, the
development of atherosclerosis are known and they occur
as a result of differences in hormones, lipid profile,
myocardial, endothelial, and vascular performance
between male and female gender and aging [16].
Relatively little is known about the effect of sex
hormones on HO activity. Demonstration of gender based
changes in the present study supports the idea of active
contribution of placenta to metabolism of maternal
during pregnancy.
The findings of present study indicate that a balance of
pro- and antiangiogenic proteins is necessary for a
successful pregnancy and any increase in antiangiogenic
factors may result in preeclampsia.
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CONCLUSION
Demonstration of gender based changes in the present
study supports the idea of active contribution of placenta
to metabolism of maternal during pregnancy. The
findings of present study indicate that a balance of pro-
and antiangiogenic proteins is necessary for a successful
pregnancy and any increase in antiangiogenic factors may
result in preeclampsia. These markers of angiogenic
balance may serve as diagnostic marker and may help in
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